Role of [18F]-FDG PET-CT in the management of the head and neck cancers;Intérêt de la TEP-TDM au [18F]-FDG dans la prise en charge des cancers des voies aérodigestives supérieures

Bulletin du Cancer

Volumn 93, Issue 10, 2006, Pages 1017-1025

  Fakhry, Nicolas ^a   Barberet, Marie ^a   Lussato, David ^a   Cammilleri, Serge ^a   Mundler, Olivier ^a   Giovanni, Antoine ^a   Zanaret, Michel ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Cancer; FDG PET; Head and neck; Upper aero digestive tract

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER RECURRENCE; CANCER STAGING; CERVICAL LYMPHADENOPATHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FOLLOW UP; HEAD AND NECK CANCER; HEALTH SURVEY; HISTOLOGY; HUMAN; POSITRON EMISSION TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; ULTRASOUND; AGED; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EVALUATION; FEMALE; HEAD AND NECK TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING;

AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 33750703959     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2006.0033     Document Type: Article

References (44)

1. Ak I, Stokkel MP, Pauwels EK. Positron emission tomography with 2-(18F) fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 2000; 126: 560-74.
2. Schmid DT, Stoeckli SJ, Bandhauer F, Huguenin P, Schmid S, von Schulthess GK, et al. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope 2003; 113: 888-91.
3. Schechter NR, Gillenwater AM, Byers RM, Garden AS, Morrison WH, Nguyen LN, et al. Can positron emission tomography improve the quality of care for head-and-neck cancer patients? Int J Radiat Oncol Biol Phys 2001; 51: 4-9.
4. McGuirt WF, Greven K, Williams D, Keyes Jr. JW, Watson N, Cappellari JO, et al. PET scanning in head and neck oncology: a review. Head Neck 1998; 20: 208-15.
5. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999; 109: 880-5.
6. Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 2004; 101: 2641-9.
7. Ha PK, Hdeib A, Goldenberg D, Jacene H, Patel P, Koch W, et al. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006; 132: 12-6.
8. Goerres GW, Schmid DT, Bandhauer F, Huguenin PU, von Schulthess GK, Schmid S, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2004; 130: 105-9 [discussion 120-1].
9. Conessa C, Herve S, Foehrenbach H, Poncet JL. FDG-PET scan in local follow-up of irradiated head and neck squamous cell carcinomas. Ann Otol Rhinol Laryngol 2004; 113: 628-35.
10. Kunkel M, Forster GJ, Reichert TE, Jeong JH, Benz P, Bartenstein P, et al. Detection of recurrent oral squamous cell carcinoma by [18F]-2- fluorodeoxyglucose-positron emission tomography: implications for prognosis and patient management. Cancer 2003; 98: 2257-65.
11. Bourguet P, Groupe de Travail SOR. Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in cancer of the upper aerodigestive tract. Bull Cancer 2003; 90 (Spec.): S67-S79.
12. Zanation AM, Sutton DK, Couch ME, Weissler MC, Shockley WW, Shores CG. Use, accuracy, and implications for patient management of [18F]-2- fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors. Laryngoscope 2005; 115: 1186-90.
13. Goshen E, Davidson T, Yahalom R, Talmi YP, Zwas ST. PET/CT in the evaluation of patients with squamous cell cancer of the head and neck. Int J Oral Maxillofac Surg 2006; 35: 332-6.
14. Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004; 231: 65-72.
15. Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF, et al. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med 2005; 46: 1136-43.
16. Stokkel MP, Terhaard CH, Hordijk GJ, van Rijk PP. The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography. Eur J Nucl Med 1999; 26: 767-73.
17. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulations tissues and cancer cells by the dynamics of fluorine-18- fuorodeoxyglucose uptake. J Nucl Med 1994; 35: 104-12.
18. Nakaraoto Y, Tatsumi M, Hammoud D, Cohade C, Osman MM, Wahl RL. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005; 234: 879-85.
19. Syed R, Bomanji JB, Nagabhushan N, Hughes S, Kayani I, Groves A, et al. Impact of combined 18F-FDG PET/CT in head and neck tumours. Br J Cancer 2005; 92: 1046-50.
20. Ryan WR, Fee Jr. WE, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005; 115: 645-50.
21. Lonneux M. Progrès en imagerie des tumeurs de la sphère cervicomaxillofaciale: la tomographie par émission de positons (TEP-Scan). Cancer Radiother 2005; 9: 8-15.
22. Kitagawa Y, Nishizawa S, Sano K, Ogasawara T, Nakamura M, Sadato N, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med 2003; 44: 198-206.
23. Brouwer J, De Bree R, Comans EF, Castelijns JA, Hoekstra OS, Leemans CR. Positron emission tomography using [18F]fluorodeoxyglucose (FDG-PET) in the clinically negative neck: is it likely to be superior? Eur Arch Otorhinolaryngol 2004; 261: 479-83.
24. Civantos FJ, Gomez C, Duque C, Pedroso F, Goodwill WJ, Weed DT, et al. Sentinel node biopsy in oral cavity cancer: correlation with PET scan and immunohistochemistry. Head Neck 2003; 25: 1-9.
25. Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 2003; 44: 1301-14.
26. Gutzeit A, Antoch G, Kuhl H, Egelhof T, Fischer M, Hauth E, et al. Unknown primary tumors: detection with dual-modality PET/CT-initial experience. Radiology 2005; 234: 227-34.
27. Nanni C, Rubello D, Castellucci P, Farsad M, Franchi R, Toso S, et al. Role of (18)F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. Eur J Nucl Med Mol Imaging 2005; 32: 589-92.
28. Bohuslavizki KH, Klutmann S, Kroger S, Sonnemann U, Buchert R, Werner JA, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000; 41: 816-22.
29. AAssar OS, Fischbein NJ, Caputo GR, Kaplan MJ, Price DC, Singer MI, et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999; 210: 177-81.
30. Bourguet P, Groupe de travail SOR. Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in unknown primary neoplasms. Bull Cancer 2003; 90(Spec.): S103-4.
31. Miller FR, Hussey D, Beeram M, Eng T, McGuff HS, Otto RA. Positron emission tomography in the management of unknown primary head and neck carcinoma. Arch Otolaryngol Head Neck Surg 2005; 131: 626-9.
32. Terhaard CH, Bongers V, van Rijk PP, Hordijk GJ. F-18-fluoro-deoxyglucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck 2001; 23: 933-41.
33. Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000; 110: 1493-7.
34. Anzai Y, Carroll WR, Quint DJ, Bradford CR, Minoshima S, Wolf GT, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996; 200: 135-41.
35. Kubota K, Yokoyama J, Yamaguchi K, Ono S, Qureshy A, Itoh M, et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging 2004; 31: 590-5.
36. Yao M, Graham MM, Smith RB, Dornfeld KJ, Skwarchuk M, Hoffman HT, et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. Int J Radiat Oncol Biol Phys 2004; 60: 1410-8.
37. Porceddu SV, Jarmolowski E, Hicks RJ, Ware R, Weih L, Rischin D, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer. Head Neck 2005; 27: 175-81.
38. Rogers JW, Greven KM, McGuirt WF, Keyes Jr. JW, Williams DW, Watson NE, et al. Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have negative PET scan after definitive radiation therapy? Int J Radiat Oncol Biol Phys 2004; 58: 694-7.
39. McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, et al. Positron emission tomography with 18F-Fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotheray in head and neck cancer. Head Neck 2004; 26: 890-6.
40. Farber LA, Benard F, Machtay M, Smith RJ, Weber RS, Weinstein GS, et al. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope 1999; 109: 970-5.
41. Lowe VJ, Boyd JH, Dunphy FR, Kim H, Dunleavy T, Collins BT, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000; 18: 651-8.
42. Wong RJ, Lin DT, Schoder H, Patel SG, Gonen M, Wolden S, et al. Diagnostic and prognostic value of [18F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20: 4199-208.
43. McGuirt WF, Greven KM, Keyes Jr. JW, Williams DW, Watson N. Laryngeal radionecrosis versus recurrent cancer: a clinical approach. Ann Otol Rhinol Laryngol 1998; 107: 293-6.
44. Zimmer LA, Snyderman C, Fukui MB, Blodgett T, McCook B, Townsend DW, et al. The use of combined PET/CT for localizing recurrent head and neck cancer: The Pittsburgh experience. Ear Nose Throat J 2005; 84: 104-10.